BTX-1801 kills certain bacteria in vitro and may well work in people to prevent common surgical site infections. BOT is doing a small Phase 2 clinical trial now at a hospital in Perth, so we will know quite soon. The clinical trials will eventually tell us if and when syzygy is achieved, and just because some members of a family of molecules also have mind altering properties doesn't prove anything either way.
- Forums
- ASX - Short Term Trading
- Short Term Trading Week Starting: 23 Nov
Short Term Trading Week Starting: 23 Nov, page-19
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)